Wall Street Zen lowered shares of Liminatus Pharma (NASDAQ:LIMN - Free Report) from a hold rating to a sell rating in a research note published on Saturday.
Liminatus Pharma Trading Down 3.5%
Liminatus Pharma stock traded down $0.18 during mid-day trading on Friday, hitting $4.91. The company's stock had a trading volume of 187,203 shares, compared to its average volume of 557,794. Liminatus Pharma has a 1 year low of $4.20 and a 1 year high of $33.66.
Liminatus Pharma Company Profile
(
Get Free Report)
Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.
See Also
Before you consider Liminatus Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Liminatus Pharma wasn't on the list.
While Liminatus Pharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access